Gemini Therapeutics GMTX

$ 1.56 0.97%

Quarterly report 2024-Q3
added 11-12-2024

Gemini Therapeutics Balance Sheet 2011-2024 | GMTX

Annual Balance Sheet Gemini Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-358 M	-193 M	-86.4 M	-1.21 M	-	-	-	-	-	-	-	-	-
Long Term Debt	1.44 M	1.03 M	1.33 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	665 K	307 K	319 K	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Current Liabilities	21.4 M	22.6 M	13.4 M	598 K	-	-	-	-	-	-	-	-	-
Total Liabilities	22.9 M	23.6 M	14.8 M	4.82 M	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-189 M	-112 M	-65.4 M	-	-	-	-	-	-	-	-	-	-
Total Assets	368 M	200 M	92.4 M	122 M	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	360 M	195 M	88 M	1.21 M	-	-	-	-	-	-	-	-	-
Book Value	345 M	177 M	77.7 M	117 M	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	345 M	177 M	-64.2 M	-21.9 M	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Gemini Therapeutics

	2024-Q3	2024-Q2	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	1.71 M	1.08 M	1.44 M	1.61 M	1.77 M	945 K	1.03 M	-	-	-	-	-	-	-	14 M	14 M	14 M	14 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	27.2 M	21.4 M	22.9 M	17.5 M	13 M	10.9 M	23.6 M	1.46 M	6.44 M	12.7 M	15.6 M	14.7 M	14.7 M	18.2 M	30.2 M	30.2 M	30.2 M	30.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-269 M	-242 M	-189 M	-165 M	-151 M	-135 M	-112 M	-210 M	-207 M	-200 M	-185 M	-167 M	-148 M	-132 M	-113 M	-113 M	-113 M	-113 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	495 M	510 M	368 M	376 M	384 M	244 M	200 M	106 M	113 M	124 M	140 M	156 M	172 M	189 M	8.32 M	8.32 M	8.32 M	8.32 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	193 M	281 M	360 M	371 M	378 M	236 M	195 M	55.6 M	65.3 M	74.5 M	137 M	150 M	168 M	185 M	4.5 M	4.5 M	4.5 M	4.5 M	3.31 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	468 M	489 M	345 M	359 M	371 M	233 M	177 M	105 M	107 M	112 M	125 M	141 M	158 M	171 M	-21.9 M	-21.9 M	-21.9 M	-21.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	468 M	489 M	345 M	359 M	371 M	233 M	177 M	-98.5 M	-82.8 M	-73.7 M	125 M	141 M	158 M	171 M	-21.9 M	-21.9 M	-21.9 M	-21.9 M	-10.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency